Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Inhibition of DHODH The final products a n were
2020-08-21

Inhibition of DHODH The final products 7a–n were assessed for their DHODH inhibitory activity on rat liver mitochondrial/microsomal membranes. A procedure adapted from the literature was employed (see Experimental), in which oxidation of DHO to ORO is monitored by following the concomitant reduct
-
The homologous DDRs are composed of an
2020-08-21

The homologous DDRs are composed of an N-terminal discoidin homology domain, followed by a sequence of ∼220 amino acids unique to the DDRs, a transmembrane domain, a large juxtamembrane domain, and a conserved cytoplasmic tyrosine kinase domain. In a previous study, we demonstrated that DDR activati
-
CYP A is involved in the
2020-08-21

CYP3A is involved in the metabolism of approximately 50% of all drugs that are currently prescribed to patients [1], [15], [16]. Marked interindividual variabilitity of the catalytic function for metabolizing CYP3A substrates has been demonstrated with variability exceeding 20-fold [1]. Levonorgestr
-
Compound was generated using a literature procedure
2020-08-21

Compound was generated using a literature procedure and required two-step Dess–Martin-periodinane/Pinnick oxidation prior to the methylation of the sulfonamide. Compound () was obtained from the Suzuki coupling of the methyl ester intermediate (en route to calcitonin receptor ). Hydrolysis of al
-
GDC-0834 The period of status survived before transition and
2020-08-21

The GDC-0834 of status survived before transition and its censorship were required to be identified. Referring to the extracted data set in Table 1, the system started to operate at 10:30 with the status 1111 and then changed to the status 1112 at 12:00. The period for the transitional status 1111→1
-
These cognitive deficits may suggest that
2020-08-21

These cognitive deficits may suggest that cognitive therapy and pharmacotherapy for gambling behavior may ultimately wish to consider genotyping as a means of better targeting treatment approaches. If core cognitive deficits are shown consistently in certain subgroups of gamblers based on genotype,
-
We did not find any
2020-08-21

We did not find any significant associations between APOE genotype and BDI-II, BAI, or PAI clinical scale scores. Our results indicate that APOE is not likely to play a major role in psychiatric comorbidities in epilepsy. This is in line with studies in the general population, which have not found a
-
The mechanisms by which Cav enhances
2020-08-21

The mechanisms by which Cav-1 enhances embryonal tumor progression are currently unknown. Given the documented ability of Cav-1 to drive increased biogenesis of caveolae and accelerate the flow of nutrients (mostly glucose and fatty acids) across the membrane, as observed in particular in adipocytes
-
Similar to EGFR another receptor
2020-08-20

Similar to EGFR, another receptor tyrosine kinase (RTK), fibroblast growth factor receptor 4 (FGFR4), is gaining attention in the lung cancer setting. The protein expression of this receptor has been recently associated with a negative impact on lung cancer prognosis, supporting the idea that FGFR4
-
br Author Contributions br Acknowledgments br
2020-08-20

Author Contributions Acknowledgments Introduction Many anticancer agents bind covalently to DNA, introduce bulky adducts, and inhibit DNA metabolic processes including repair, replication and transcription.1., 2., 3. Frequently, the first enzymes to encounter DNA adducts are DNA helicases.
-
novobiocin To understand more clearly how these activities
2020-08-20

To understand more clearly how these activities are combined in the heterotrimeric enzyme and to understand more clearly how DNA alkylation might effect DNA helicase activity, we summarize the relevant features of the structure of RecBCD determined in the presence of DNA. The RecB and RecC subunits
-
Autophagy alterations are frequently reported as one of the
2020-08-20

Autophagy alterations are frequently reported as one of the pathological mechanisms contributing to neurodegenerative diseases, due to incomplete removal of protein Calcitriol mg in the brain [30,41]. It was over a decade ago when mutations in PARK8 encoding for the LRRK2 protein were described as a
-
Ligand independent constitutively active variants have
2020-08-20

Ligand-independent, constitutively active variants have also been found in receptors with associated tyrosine kinases. In approximately 60% of patients harboring inflammatory hepatocellular adenomas (IHCAs), these adenomas have been caused by small in-frame deletions in the cytokine-binding domain o
-
Proteases as multifunctional enzymes play key roles
2020-08-20

Proteases, as multifunctional enzymes, play key roles in controlling a wide variety of cellular and extracellular processes in plants and animals, including protein degradation and processing, germination, complement activation, inflammation, responses to environmental stimuli, senescence and so on.
-
Finally unilateral microinjection of CP Astressin B CP CRF o
2020-08-20

Finally, unilateral microinjection of CP-376395, Astressin 2B, CP-376395 + CRF or ASTR 2B + CRF into the BLA (Fig. 3A) or CeA (Fig. 3B) did not significantly alter spontaneous motor activity in the open field test (F4,24 = 0.148, P > 0.05; F4,29 = 0.290, P > 0.05 in the BLA and CeA, respectively, AN
16388 records 840/1093 page Previous Next First page 上5页 836837838839840 下5页 Last page